HELPING THE OTHERS REALIZE THE ADVANTAGES OF TARLOX-TKI

Nilotinib is currently accepted by FDA as front-line therapy for chronic stage CML and for sufferers who will be resistant or intolerant to imatinib.The impressive final results shown with imatinib mesylate (aka Gleevec) targeting split point cluster (Bcr)-Abelson (Abl) fusion protein in Long-term myeloid leukemia (CML) result in the development of